For the full year 2024, Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, delivered revenues of NOK 531.3, which is 3.8 per ...
D illustration of bacteriaphages attacking bacteria. Courtesy Getty Images.In the face of rising concerns about antibiotic ...
"Conducting research through the SEA-PHAGES program was the first time in my academic career where I felt what I learned in ...
The Harvard Pilgrim Health Care Institute is proud to announce the launch of the Center for Sepsis Epidemiology and ...
Photodynamic inactivation using curcumin shows promise in reducing antibiotic resistance diversity in Staphylococcus aureus, ...
By combining MERFISH imaging with expansion microscopy, researchers have unlocked a new way to study bacteria at the ...
An antibiotic used to treat infective diarrhea could be an effective drug for a type of inflammatory bowel disease, a new ...
Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.
When managing an irritated cornea, choosing among fortified antibiotics, oral antivirals, anti-inflammatories or combination ...
AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...
Addresses the significant threat of antimicrobial resistance.
The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback